Cardiff Oncology (CRDF) Total Non-Current Liabilities (2011 - 2022)

Cardiff Oncology has reported Total Non-Current Liabilities for 12 years, with the latest figure at $9.8 million in Q4 2022.

• Quarterly Total Non-Current Liabilities rose 7.9% year-over-year to $9.8 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $9.8 million (up 7.9% YoY) and the FY2022 annual result came in at $9.8 million, up 7.9% from the prior year.
• Total Non-Current Liabilities improved to $9.8 million in Q4 2022 per CRDF's latest filing, from $9.1 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $9.8 million in Q4 2022 and troughed at $3.9 million in Q3 2018.
• A 5-year average of $5.7 million and a median of $5.3 million in 2019 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2018 and 2021: Total Non-Current Liabilities slumped 78.44% in 2018, then jumped 45.24% in 2021.
• Over 5 years, Total Non-Current Liabilities stood at $4.1 million in 2018, then jumped by 42.29% to $5.8 million in 2019, then increased by 8.89% to $6.3 million in 2020, then surged by 45.24% to $9.1 million in 2021, then gained by 7.9% to $9.8 million in 2022.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $9.8 million, $9.1 million, and $7.7 million for Q4 2022, Q4 2021, and Q3 2021 respectively.